ID: ALA5275717

Max Phase: Preclinical

Molecular Formula: C30H17ClF2N4O2S

Molecular Weight: 571.01

Representations

Canonical SMILES:  O=c1oc2ccc(F)cc2cc1-c1csc(N2N=C(c3cccc(F)c3)CC2c2cc3ccccc3nc2Cl)n1

Standard InChI:  InChI=1S/C30H17ClF2N4O2S/c31-28-22(12-17-4-1-2-7-23(17)34-28)26-14-24(16-5-3-6-19(32)10-16)36-37(26)30-35-25(15-40-30)21-13-18-11-20(33)8-9-27(18)39-29(21)38/h1-13,15,26H,14H2

Standard InChI Key:  PYVUHZAGYZBGKK-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 571.01

Molecular Weight (Monoisotopic): 570.0729

AlogP: 7.75

#Rotatable Bonds: 4

Polar Surface Area: 71.59

Molecular Species: NEUTRAL

HBA: 7

HBD: 0

#RO5 Violations: 2

HBA (Lipinski): 6

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 3.60

CX LogP: 7.89

CX LogD: 7.89

Aromatic Rings: 6

Heavy Atoms: 40

QED Weighted: 0.16

Np Likeness Score: -1.44

References

1. Nehra B, Rulhania S, Jaswal S, Kumar B, Singh G, Monga V..  (2020)  Recent advancements in the development of bioactive pyrazoline derivatives.,  205  [PMID:32795767] [10.1016/j.ejmech.2020.112666]

Source

Source(1):

• Scientific Literature